GOP lawmaker pushes back on Trump drug pricing proposal

GOP lawmaker pushes back on Trump drug pricing proposal
© Greg Nash

Rep. Larry BucshonLarry Dean BucshonGOP balks at Trump drug pricing plan Overnight Health Care: Trump officials allow states to loosen ObamaCare coverage requirements | GOP lawmakers air concerns with Trump drug price plan | Dem single-payer fight shifting to battle over Medicare 'buy-in' | US life expectancy falls GOP lawmakers air concerns with Trump drug pricing move in meeting with health chief MORE (R-Ind.) on Friday criticized a drug pricing proposal President TrumpDonald John TrumpTrump knocks BuzzFeed over Cohen report, points to Russia dossier DNC says it was targeted by Russian hackers after fall midterms BuzzFeed stands by Cohen report: Mueller should 'make clear what he's disputing' MORE made last month, marking some of the first public resistance to the move from congressional Republicans.

Bucshon told The Hill that Trump’s proposal to lower some drug prices in Medicare by tying them to cheaper prices in other countries is too far of a move toward “price controls.”

ADVERTISEMENT
“It's not the direction that I would take,” Bucshon, a member of the House Energy and Commerce Committee, which oversees the issue, said. “I understand that we do want to get drug prices down but I think that any proposal that would lead to government price-fixing in that space is a pathway we don't want to follow.”

Trump’s move, announced in October, went farther in the direction of price controls on drugs than what Republicans typically support. Some Democrats praised his move, but cautioned that it did not go far enough.

But many Republicans could be hesitant to publicly criticize President Trump over the move, and some support it.

House Ways and Means Committee Chairman Kevin BradyKevin Patrick BradyTexas governor, top lawmakers tell Trump not to use hurricane relief funds to build border wall Trump on declaring national emergency: 'Not going to do it so fast' Dems look to chip away at Trump tax reform law MORE (R-Texas) said on Tuesday that he is still “assessing” the proposal, without praising or criticizing it.

Bucshon said other GOP lawmakers have concerns, too, without naming them. “I think a lot of people have concerns about it,” he said.

The pharmaceutical industry, which has long been a powerful force in Congress, strongly opposes the proposal. Steve Ubl, the CEO of the Pharmaceutical Research and Manufacturers of America, said last month that the proposal is “imposing foreign price controls from countries with socialized health care systems that deny their citizens access and discourage innovation.”

Asked if Congress has a role in potentially overruling the proposal, Bucshon said, “I don’t know yet.”

“That's above my paygrade to think about that, but there's ongoing discussions between the administration and people on our committee at higher levels and we'll see where it goes,” he added.

House Energy and Commerce Committee Chairman Greg WaldenGregory (Greg) Paul WaldenHillicon Valley: Republicans demand answers from mobile carriers on data practices | Top carriers to stop selling location data | DOJ probing Huawei | T-Mobile execs stayed at Trump hotel as merger awaited approval House Republicans question mobile carriers on data practices On The Money: Trump says he won't declare emergency 'so fast' | Shutdown poised to become longest in history | Congress approves back pay for workers | More federal unions sue over shutdown MORE (R-Ore.) has not publicly commented on the specifics of the proposal, though he released a statement after it was announced praising Trump’s commitment on drug pricing in general terms.

Sen. Lamar AlexanderAndrew (Lamar) Lamar AlexanderMcConnell blocks House bill to reopen government for second time Senators restart shutdown talks — and quickly hit roadblocks GOP senators propose bill to pay 'excepted' workers during shutdown MORE (R-Tenn.), the chairman of the Senate’s health committee, said last month he was “encouraged” by the proposal, making him a key supporter in Congress.

Bucshon helped lead opposition to a somewhat similar Medicare drug pricing proposal from former President Obama in 2016. The Obama administration eventually dropped the proposal in the face of opposition from Congress, the drug industry, and some doctors. 

Bucshon said he had not yet had a chance to discuss his concerns that the move would harm patients' access to innovative new drugs with the administration, but that the GOP Doctors Caucus, of which he is a member, would probably meet with Secretary of Health and Human Services Alex Azar after Thanksgiving.